Evidence map›Paper›PMID 31882469›Full record

ArticleIn vivo (Athens, Greece)

Clinical Significance of Ubiquitin-associated Protein 2-like in Patients With Uterine Cervical Cancer.

Kosuke Yoshida, Hiroaki Kajiyama, Eri Inami, Satoshi Tamauchi, Yoshiki Ikeda, Nobuhisa Yoshikawa, Kimihiro Nishino, Fumi Utsumi, Kaoru Niimi, Shiro Suzuki and 3 more

Open access · diamondAbstract read
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. OGT controls mammalian cell viability by regulating the proteasome/mTOR/ mitochondrial axis.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  4. Ubiquitin Binding Protein 2-Like (UBAP2L): is it so NICE After All?Frontiers in cell and developmental biology · 2022
    Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Kosuke YoshidaDepartment of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Hiroaki KajiyamaDepartment of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Nagoya, Japan kajiyama@med.nagoya-u.ac.jp.
Eri InamiBell Research Center for Reproductive Health and Cancer, Nagoya, Japan.
Satoshi TamauchiDepartment of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Yoshiki IkedaDepartment of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Nobuhisa YoshikawaDepartment of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Kimihiro NishinoDepartment of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Fumi UtsumiDepartment of Obstetrics and Gynecology, Fujita Health University Bantane Hospital, Nagoya, Japan.
Kaoru NiimiDepartment of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Shiro SuzukiDepartment of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Kiyosumi ShibataDepartment of Obstetrics and Gynecology, Fujita Health University Bantane Hospital, Nagoya, Japan.
Akihiro NawaBell Research Center for Reproductive Health and Cancer, Nagoya, Japan.
Fumitaka KikkawaDepartment of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Nagoya University · JPFujita Health University Bantane Hospital

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundUbiquitin-associated protein 2-like (UBAP2L) has been demonstrated to be associated with the progression of multiple types of cancer. However, the function of UBAP2L in uterine cervical cancer remains unclear. MATERIALS AND

methodsBetween 2005 and 2015, 84 patients who underwent surgery were included in this study. The patients were stratified into two groups on the basis of immunohistochemical staining for UBAP2L, and survival analysis was performed. Moreover, loss-of-function analysis was performed using the cervical cancer cell lines CaSki and SiHa.

resultsBased on immunohistochemistry, the overall survival in patients with low UBAP2L expression was significantly longer than that of those with high UBAP2L expression (p=0.045). The in vitro experiment revealed that knockdown of UBAP2L remarkably inhibited cell proliferation in both live cell imaging and the MTS assay.

conclusionPatients with high UBAP2L expression had unfavorable prognosis and UBAP2L appears to play an important role in proliferation.

Indexed as

AdultAgedCarrier ProteinsCell Line, TumorCell ProliferationFemaleGene Expression Regulation, NeoplasticGene Knockdown TechniquesHumansMiddle AgedPrognosisRNA, Small InterferingUterine Cervical NeoplasmsYoung AdultCarrier ProteinsRNA, Small InterferingUbap2L protein, humanCervical cancerprognostic factorproliferationRNA interferenceubiquitin-associated protein 2-like

Identifiers

PMID31882469
PMCPMC6984086
OpenAlexW2998104098

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.